Journal of Biopharmaceutical Statistics

Aims & Scope

The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development.

Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor.

Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	1.2
2024	1.20

Journal Rank

Year	Value
2024	10292

Journal Citation Indicator

Year	Value
2024	242

SJR (SCImago Journal Rank)

Year	Value
2024	0.565

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	58

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Mathematics, Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Agreement Between Methods of Measurement with Multiple Observations Per Individual

  Citation: 1505

  Authors: J. Martin, Douglas G.

• Weighted Gene Coexpression Network Analysis: State of the Art

  Citation: 326

  Authors: Wei, Peter, Tova, Jun, Ai, Steve

• ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS

  Citation: 320

  Authors: Craig H., W. Scott, Stacy R.

• MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets

  Citation: 269

  Authors: Ohidul, H. M. James, Robert

• An Overview on Assessing Agreement with Continuous Measurements

  Citation: 266

  Authors: Huiman X., Michael J., Lawrence I.

• Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group

  Citation: 241

  Authors: Paul, Christy, Vladimir, Brenda, Michael, José

• Analysis of Longitudinal Trials with Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and Inference via Multiple Imputation

  Citation: 226

  Authors: James R., James H., Michael G.

• On the Use of Zero-Inflated and Hurdle Models for Modeling Vaccine Adverse Event Count Data

  Citation: 193

  Authors: C. E., S. W., K. A., B. D.

• Practical modifications of the continual reassessment method for phase i cancer clinical trials

  Citation: 181

  Authors: Douglas

• Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials

  Citation: 166

  Authors: Björn, Frank, Alex, Greg, Brenda, Chyi-Hung, Franz, Michael, Qing, Beat, Tom, José, Amit, Rick, Frank

---